Shin Yasui

Shin Yasui

Auto-generated profile, based on publicly available information

Shin Yasui

Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2008 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
KFKeiichi Fujiwara
Keiichi Fujiwara
SYShin Yasui
Shin Yasui
YYYutaka Yonemitsu
Yutaka Yonemitsu
KFKenichi Fukai
Kenichi Fukai
MAMakoto Arai
Makoto Arai
OYOsamu Yokosuka
Osamu Yokosuka

5 May 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MNMasato Nakamura
Masato Nakamura
Tatsuo KandaTatsuo Kanda
Tatsuo Kanda
ZZZengren Zhao
Zengren Zhao
YHYuki Haga
Yuki Haga
KTKoji Takahashi
Koji Takahashi
OYOsamu Yokosuka
Osamu Yokosuka
Noninvasive methods to accurately and conveniently evaluate liver fibrosis are desirable. MicroRNA (miR) is one of the candidates. MiRs are small RNAs consisting of 19–25 nucleotides that negatively regulate many target genes at transcriptional levels. Recently, many researchers have focused on circulating miRs in the blood stream as biomarkers. Hepatic miR-122 has been reported to have an association with viral replication and hepatic fibrosis in chronic hepatitis B virus (HBV) and hepatic C virus (HCV) infection. We measured serum miR-122 levels in HBV- and HCV-infected patients confirmed with liver biopsy. We also investigated a novel liver fibrosis marker Wisteria floribunda agglutinin-positive Mac-2 binding protein [WFA(+)-M2BP]. We evaluated the diagnostic usefulness of these markers in hepatic fibrosis and inflammation of patients with chronic viral infection. The serum miR-122 levels of HBV-infected patients were higher than those of the control subjects. In HBV-infected patients, the serum miR-122 levels of patients with advanced liver fibrosis were significantly lower. Serum WFA(+)-M2BP was significantly higher dependent on both the staging of fibrosis and the grading of inflammatory activity in patients with both HBV and HCV infection. We also observed that higher serum WFA(+)-M2BP levels augmented the prediction of advanced liver fibrosis among HBV-infected patients with lower serum miR-122 levels. A lower serum miR-122 level is a useful predictor of advanced liver fibrosis in HBV-infected patients. Serum WFA(+)-M2BP could predict liver fibrosis in both HBV and HCV infection. The combination of these markers may result in the more accurate evaluation of liver fibrosis in HBV infection.

20 December 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JKJunichiro Kumagai
Junichiro Kumagai
TTTakashi Taida
Takashi Taida
SOSadahisa Ogasawara
Sadahisa Ogasawara
TNTomoo Nakagawa
Tomoo Nakagawa
YIYotaro Iino
Yotaro Iino
NKNaoya Kato
Naoya Kato
In Western countries, most patients with primary sclerosing cholangitis (PSC) have concurrent ulcerative colitis (UC). The number of patients with UC in East Asia has increased markedly over the past two decades. However, current clinical features of PSC and of PSC associated with UC (PSC-UC) have not yet been clarified in East Asia, particularly in Japan. We aimed to reveal the clinical courses and associations with UC in Japanese patients with PSC from the mutual viewpoint of PSC and UC. We retrospectively retrieved medical records of patients with PSC (69) and UC (1242) who were diagnosed at Chiba University Hospital between June 1991 and August 2017. In the present cohort, 37 patients had PSC-UC; the cumulative risks of PSC in patients with UC and of UC in patients with PSC were 3.0% and 53.6%, respectively. We confirmed similar distinctive results by a Japanese nationwide survey, noting that younger patients with PSC had a notably high possibility of association with UC. From the viewpoint of the UC cohort, the occurrence of right-sided disease was significantly higher in patients with PSC-UC than in those with UC (16.2% vs. 4.2%, P = 0.003). Pancolitis was more commonly observed in PSC-UC, and proctits/left-sided colitis was less commonly found in patients with UC. The number of patients with young-onset PSC-UC may be increasing similar to an increase in patients with UC in Japan. In our cohort, the comorbidity rate of PSC-UC was higher than that obtained in previous reports. The incidence of PSC-UC and UC may increase in the future in East Asia, particularly in Japan.

1 January 2016 in International Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
Tatsuo KandaTatsuo Kanda
Tatsuo Kanda
SYShin Yasui
Shin Yasui
MNMasato Nakamura
Masato Nakamura
ESEiichiro Suzuki
Eiichiro Suzuki
MAMakoto Arai
Makoto Arai
OYOsamu Yokosuka
Osamu Yokosuka
Background. All-oral combination of direct-acting antivirals could lead to higher sustained virologic response (SVR) in hepatitis C virus (HCV)-infected patients. In the present study, we examined the efficacy and safety of the dual oral treatment with HCV nonstructural protein (NS) 5A inhibitor daclatasvir (DCV) plus HCV NS3/4A inhibitor asunaprevir (ASV) for 24 weeks in real-world HCV genotype 1-infected Japanese individuals.

30 March 2011 in Hepatology
Verified
Journal Article
Open access
PDF file
KFKeiichi Fujiwara
Keiichi Fujiwara
SYShin Yasui
Shin Yasui
OYOsamu Yokosuka
Osamu Yokosuka

21 April 2014 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
SYS. Yasui
S. Yasui
KFK. Fujiwara
K. Fujiwara
MNMasato Nakamura
Masato Nakamura
TMT. Miyamura
T. Miyamura
YYY. Yonemitsu
Y. Yonemitsu
OYO. Yokosuka
O. Yokosuka